Heartflow to Participate in the Wells Fargo 21st Annual Healthcare Conference

Rhea-AI Summary

Heartflow (Nasdaq: HTFL) announced that its management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference in Boston on September 9, 2026, at 3:45 p.m. ET. A live and archived webcast will be available in the Investor Relations section of Heartflow’s website. The company will also highlight its AI-based Heartflow One platform for coronary artery disease diagnosis and management.

Market Context

Historical reactions ranged from -12.17% to 35.79% across recent events, adding variability context ...

Analysis

Historical reactions ranged from -12.17% to 35.79% across recent events, adding variability context to this scheduled appearance. Recent activity was classified as Net Selling; conference remarks and execution remain watch items.

Key Figures

Institution adoption: more than 1,800 institutions Peer-reviewed publications: more than 625 publications Patients managed: over 750,000 patients +5 more

8 metrics

Institution adoption more than 1,800 institutions globally

Peer-reviewed publications more than 625 publications supporting Heartflow technology and research

Patients managed over 750,000 patients worldwide

Annotated CTA images more than 200 million images proprietary coronary imaging dataset

Clinical studies over 200 studies clinical and real-world validation

Validated patients over 365,000 patients across more than 200 studies

Image acceptance rate exceed 97% coronary CTA image acceptance rates

Cardiovascular event risk 2.5x increase cardiovascular events or deaths at 7 years in a 900-patient study

Historical Context

5 past events · Latest: Aug 13 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 13	Q2 earnings report	Positive	+35.8%	Revenue growth and raised full-year guidance preceded a 35.79% 24-hour gain.
Jul 23	Earnings date notice	Neutral	-2.0%	The company scheduled its Q2 results release and conference call for August 13.
Jul 09	Clinical data update	Positive	+6.0%	New plaque-analysis data supported risk reclassification and longitudinal tracking across CT scanners.
May 14	Q1 earnings report	Positive	-12.2%	Revenue growth and raised guidance accompanied a 12.17% negative 24-hour reaction.
Apr 23	Earnings date notice	Neutral	-2.6%	The company announced its Q1 results date and scheduled the investor conference call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Positive operating or clinical updates produced mixed reactions, while earnings-date notices were followed by negative reactions.

Key Terms

HITRUST, SOC 2 Type 2, MDSAP, ISO 13485, +1 more

5 terms

HITRUST regulatory

"including HITRUST, SOC 2 Type 2, MDSAP, ISO 13485, and ISO 27001."

HITRUST is an independent organization and a widely used security and privacy framework that helps healthcare and related companies show they protect sensitive data like patient records. Think of it as a standardized lock-and-inspection checklist auditors use to confirm an organization follows strong data security and regulatory rules. For investors, HITRUST recognition reduces the risk of costly data breaches, regulatory fines, and reputational damage, making a business a safer long-term bet.

SOC 2 Type 2 regulatory

"including HITRUST, SOC 2 Type 2, MDSAP, ISO 13485, and ISO 27001."

SOC 2 Type 2 is an independent audit that verifies a service provider’s operational controls for security, availability, processing integrity, confidentiality and privacy over a sustained period. Think of it as a multi-week inspection that checks not just that security measures exist but that they actually work day to day; for investors, a clean SOC 2 Type 2 report lowers the risk of data breaches, downtime and regulatory problems and signals stronger operational reliability.

MDSAP regulatory

"including HITRUST, SOC 2 Type 2, MDSAP, ISO 13485, and ISO 27001."

The Medical Device Single Audit Program (MDSAP) is an international regulatory framework that allows one comprehensive audit of a medical device manufacturer’s quality and safety systems to satisfy inspection requirements in multiple participating countries. For investors, MDSAP matters because it reduces the risk of unexpected regulatory delays, lowers repeated inspection costs, and can speed access to several markets at once—like getting one multi-country safety check instead of many separate ones.

ISO 13485 regulatory

"including HITRUST, SOC 2 Type 2, MDSAP, ISO 13485, and ISO 27001."

ISO 13485 is an international quality management standard for organizations that design, produce, or service medical devices. Think of it as a factory’s rulebook and checklist that helps ensure products are safe, consistently made, and meet regulatory rules worldwide. For investors, certification signals lower operational and regulatory risk, easier market access, and greater reliability of a company’s medical products and supply chain — similar to buying from a trusted, inspected supplier.

ISO 27001 regulatory

"including HITRUST, SOC 2 Type 2, MDSAP, ISO 13485, and ISO 27001."

ISO 27001 is an internationally recognized standard that sets out the best practices for managing and protecting sensitive information within an organization. It acts like a security blueprint, helping companies ensure data is kept safe from theft, loss, or damage. For investors, organizations with ISO 27001 certification demonstrate a strong commitment to information security, reducing the risk of data breaches that could impact business stability and reputation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing and managing coronary artery disease (CAD), today announced that members of management will participate in a fireside chat at the upcoming Wells Fargo 21^st Annual Healthcare Conference. The fireside chat, which will include a slideshow presentation followed by a question-and-answer session, will take place in Boston on Wednesday, September 9, 2026, at 3:45 p.m. ET / 12:45 p.m. PT.

A live and archived version of the fireside chat will be available on the Investor Relations section of the Heartflow website at https://ir.heartflow.com.

About Heartflow’s Technology and Research

Heartflow’s technology is redefining precision diagnostic testing and management for coronary artery disease (CAD) through clinically-proven AI and the world’s largest coronary imaging dataset. Heartflow has been adopted by more than 1,800 institutions globally and continues to strengthen its commercial presence to make this cutting-edge solution more widely available to an increasingly diverse patient population. Backed by American College of Cardiology and American Heart Association (ACC/AHA) guidelines and supported by more than 625 peer-reviewed publications, Heartflow has redefined how clinicians manage care for over 750,000 patients worldwide.¹ Key benefits include:

• Unmatched proprietary data pipeline: Built from the world’s largest database of more than 200 million annotated CTA images, Heartflow’s data foundation powers advanced AI models that deliver highly accurate, reproducible diagnostic insights across diverse patient populations.
• Extensive clinical and real-world validation: Heartflow’s AI-driven solutions have been validated through clinical evidence in over 200 studies assessing over 365,000 patients. Heartflow is the only AI platform prospectively validated against invasive gold standards and demonstrated through real-world evidence to improve patient outcomes.^2,3,4,5 Proven in real-world practice with reproducibility and accuracy, Heartflow’s coronary CTA image acceptance rates exceed 97%.
• Seamless clinical integration via upgraded workflow: Heartflow delivers final quality-reviewed analyses instantly upon order, enabling clinicians to move from diagnosis to decision without delay.
• Quality system, global security and patient-data integrity compliance: Heartflow meets or exceeds leading international standards, including HITRUST, SOC 2 Type 2, MDSAP, ISO 13485, and ISO 27001.

About Heartflow, Inc.

Heartflow is transforming coronary artery disease from the world’s leading cause of death into a condition that can be detected early, diagnosed accurately, and managed for life. The Heartflow One platform uses AI to turn coronary CTA images into personalized 3D models of the heart, providing clinically meaningful, actionable insights into plaque location, volume, and composition and its effect on blood flow — all without invasive procedures. Discover how we’re shaping the future of cardiovascular care at heartflow.com.

Investor Contact
Nick Laudico
nlaudico@heartflow.com

Media Contact
Elliot Levy
elevy@heartflow.com

^{____________________________________}

¹ Gulati M, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCAI Guideline for the Evaluation and Diagnosis of Chest Pain. Circulation 2021; 144:e368–e454.
² Narula, et al. EHJ CVI 2024.
³ Danad, et al. JAMA Cardiol 2017.
⁴ Fairbairn et al. Coronary CT Angiography Plaque as a Predictor of Death, Cardiovascular Death and Myocardial Infarction. Presented at AHA 2025. (Real-world study with n=7,899 patients, higher TPV results in increased cardiovascular death and MI).
⁵ Madsen KT, et al. ADVANCE-DK 7-year. Presented at TCT Scientific Sessions 2024. (n=900 patients determined a 2.5x increase in cardiovascular events or deaths at 7 years).

FAQ

When will Heartflow (NASDAQ: HTFL) present at the Wells Fargo 21st Annual Healthcare Conference in 2026?

Heartflow will participate in a fireside chat on September 9, 2026, at 3:45 p.m. ET. According to Heartflow, the session will be held in Boston and include a slideshow presentation followed by a question-and-answer segment with management.

How can investors access the Heartflow (HTFL) Wells Fargo Healthcare Conference webcast on September 9, 2026?

Investors can access a live and archived webcast of the Heartflow fireside chat via the Investor Relations section of heartflow.com. According to Heartflow, both real-time and replay options will be available for those unable to attend the Boston event.

What technology will Heartflow (HTFL) highlight at the Wells Fargo 21st Annual Healthcare Conference?

Heartflow plans to highlight its AI-driven Heartflow One platform for coronary artery disease diagnosis and management. According to Heartflow, the system converts coronary CTA images into personalized 3D heart models, offering non-invasive insights into plaque location, volume, composition, and blood-flow impact.

How widely is Heartflow’s AI coronary artery disease technology adopted as of August 2026?

Heartflow reports adoption at more than 1,800 institutions globally as of the announcement date. According to Heartflow, its technology has helped manage care for over 750,000 patients worldwide and is supported by ACC/AHA guidelines and over 625 peer-reviewed publications.

What clinical validation data supports Heartflow (HTFL) AI technology mentioned in the August 27, 2026 update?

Heartflow’s AI solutions have been evaluated in over 200 studies covering more than 365,000 patients. According to Heartflow, its platform is the only AI system prospectively validated against invasive gold standards and has demonstrated real-world improvements in cardiovascular outcomes and diagnostic reproducibility.